Ovarian Cyst Fluids Are a Cache of Tumor Biomarkers That Include Calgranulin A and Calgranulin B Isoforms

REFERENCES

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10–29.
   PubMed Web of Science ®Google Scholar
• Goff BA, Mandel L, Muntz HG, Melancon CH. Ovarian carcinoma diagnosis. Cancer 2000;89:2068–2075.
   PubMed Web of Science ®Google Scholar
• Menon U. Ovarian cancer screening. CMAJ 2004;171:323–324.
   PubMed Web of Science ®Google Scholar
• Runnebaum IB, Stickeler E. Epidemiological and molecular aspects of ovarian cancer risk. J Cancer Res Clin Oncol 2001;127:73–79.
   PubMed Web of Science ®Google Scholar
• Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, Reding DJ, Greenlee RT, Yokochi LA, Kessel B, Crawford ED, Church TR, Andriole GL, Weissfeld JL, Fouad MN, Chia D, O‘Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hartge P, Pinsky PF, Zhu CS, Izmirlian G, Kramer BS, Miller AB, Xu JL, Prorok PC, Gohagan JK, Berg C. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011;305:2295–2303.
   PubMed Web of Science ®Google Scholar
• Fields MM, Chevlen E. Ovarian cancer screening: a look at the evidence. Clin J Oncol Nurs 2006;10:77–81.
   PubMedGoogle Scholar
• Gaarenstroom KN, van der Hiel B, Tollenaar RA, Vink GR, Jansen FW, van Asperen CJ, Kenter GG. Efficacy of screening women at high risk of hereditary ovarian cancer: results of an 11-year cohort study. Int J Gynecol Cancer 2006;16 (Suppl 1):54–59.
   PubMed Web of Science ®Google Scholar
• Hartge P. Designing early detection programs for ovarian cancer. J Natl Cancer Inst 2010;102:3–4.
   PubMed Web of Science ®Google Scholar
• Kobel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM, Miller D, Santos J, Swenerton K, Gilks CB, Huntsman D. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008;5:e232.
   PubMed Web of Science ®Google Scholar
• Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001;22:255–288.
   PubMed Web of Science ®Google Scholar
• Ghahremani M, Foghi A, Dorrington JH. Etiology of ovarian cancer: a proposed mechanism. Med Hypotheses 1999;52:23–26.
   PubMed Web of Science ®Google Scholar
• Kurman RJ, Shih Ie M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010;34:433–443.
   PubMed Web of Science ®Google Scholar
• Knudsen UB, Tabor A, Mosgaard B, Andersen ES, Kjer JJ, Hahn-Pedersen S, Toftager-Larsen K, Mogensen O. Management of ovarian cysts. Acta Obstet Gynecol Scand 2004;83:1012–1021.
   PubMed Web of Science ®Google Scholar
• Oyelese Y, Kueck AS, Barter JF, Zalud I. Asymptomatic postmenopausal simple ovarian cyst. Obstet Gynecol Surv 2002;57:803–809.
   PubMed Web of Science ®Google Scholar
• Artini PG, Cristello F, Monti M, Cela V, Battaglia C, D'Ambrogio G, Genazzani AR. Vascular endothelial growth factor and its soluble receptor in ovarian pathology. Gynecol Endocrinol 2005;21:50–56.
   PubMed Web of Science ®Google Scholar
• Boss EA, Massuger LF, Thomas CM, Geurts-Moespot A, Boonstra H, Sweep CG. Vascular endothelial growth factor in ovarian cyst fluid. Cancer 2001;91:371–377.
   PubMed Web of Science ®Google Scholar
• Candido Dos Reis FJ, Moreira de Andrade J, Bighetti S. CA 125 and vascular endothelial growth factor in the differential diagnosis of epithelial ovarian tumors. Gynecol Obstet Invest 2002;54:132–136.
   PubMed Web of Science ®Google Scholar
• Demirkiran F, Kumbak B, Bese T, Arvas M, Benian A, Aydin S, Uzun H, Sanioglu C, Aydinli K, Kosebay D. Vascular endothelial growth factor in adnexal masses. Int J Gynaecol Obstet 2003;83:53–58.
   PubMed Web of Science ®Google Scholar
• Fasciani A, D'Ambrogio G, Bocci G, Luisi S, Artini PG, Genazzani AR. Vascular endothelial growth factor and interleukin-8 in ovarian cystic pathology. Fertil Steril 2001;75:1218–1221.
   PubMed Web of Science ®Google Scholar
• Harlozinska A, Sedlaczek P, Kulpa J, Grybos M, Wojcik E, Van Dalen A, Einarsson R. Vascular endothelial growth factor (VEGF) concentration in sera and tumor effusions from patients with ovarian carcinoma. Anticancer Res 2004;24: 1149–1157.
   PubMed Web of Science ®Google Scholar
• Hazelton D, Nicosia RF, Nicosia SV. Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy. Clin Cancer Res 1999;5:823–829.
   PubMed Web of Science ®Google Scholar
• Bischof A, Briese V, Richter DU, Bergemann C, Friese K, Jeschke U. Measurement of glycodelin A in fluids of benign ovarian cysts, borderline tumours and malignant ovarian cancer. Anticancer Res 2005;25:1639–1644.
   PubMed Web of Science ®Google Scholar
• Cherchi PL, Capobianco G, Ambrosini G, Fadda GM, Piga MD, Ruiu G, Fattorini F, Dessole S. Intracystic evaluation of tumor markers in benign and malignant ovarian pathology. Eur J Gynaecol Oncol 2002;23:163–165.
   PubMed Web of Science ®Google Scholar
• de Bruijn HW, ten Hoor KA, Boonstra H, Marrink J, Krans M, Aalders JG. Cancer-associated antigen CA 195 in patients with mucinous ovarian tumours: a comparative analysis with CEA, TATI and CA 125 in serum specimens and cyst fluids. Tumour Biol 1993;14:105–115.
   PubMed Web of Science ®Google Scholar
• Harlozinska A, Sedlaczek P, Van Dalen A, Rozdolski K, Einarsson R. TPS and CA 125 levels in serum, cyst fluid and ascites of patients with epithelial ovarian neoplasms. Anticancer Res 1997;17:4473–4478.
   PubMed Web of Science ®Google Scholar
• Lloyd KO, Yin BW, Tempst P, Erdjument-Bromage H. MUC-6 mucin is a major component of “blood group substance” from human ovarian cyst fluid. Biochim Biophys Acta 2000;1474:410–414.
   PubMed Web of Science ®Google Scholar
• Sedlaczek P, Frydecka I, Gabrys M, Van Dalen A, Einarsson R, Harlozinska A. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma. Cancer 2002;95:1886–1893.
   PubMed Web of Science ®Google Scholar
• Swierzko AS, Florczak K, Cedzynski M, Szemraj J, Wydra D, Bak-Romaniszyn L, Emerich J, Sulowska Z. Mannan-binding lectin (MBL) in women with tumours of the reproductive system. Cancer Immunol Immunother 2007;56:959–971.
   PubMed Web of Science ®Google Scholar
• Tavares Murta BM, Cunha Fde Q, Miranda R, Adad SJ, Murta EF. Differential tumor microenvironment in human ovarian cystic tumors. Tumori 2004;90:491–497.
   PubMed Web of Science ®Google Scholar
• Baykal C, Demirtas E, Al A, Ayhan A, Yuce K, Tulunay G, Kose MF, Ayhan A. Comparison of HGF (hepatocyte growth factor) levels of epithelial ovarian cancer cyst fluids with benign ovarian cysts. Int J Gynecol Cancer 2003;13:771–775.
   PubMed Web of Science ®Google Scholar
• Chudecka-Glaz A, Rzepka-Gorska I, Kosmowska B. Inhibin A levels in cyst fluid from epithelial ovarian tumors. Acta Obstet Gynecol Scand 2004;83:501–503.
   PubMed Web of Science ®Google Scholar
• Chudecka-Glaz A, Rzepka-Gorska I. Activin A levels in serum and cyst fluid in epithelial tumors of the ovary. Int J Gynaecol Obstet 2005;89:160–162.
   PubMed Web of Science ®Google Scholar
• Darai E, Detchev R, Hugol D, Quang NT. Serum and cyst fluid levels of interleukin (IL)-6, IL-8 and tumour necrosis factor-alpha in women with endometriomas and benign and malignant cystic ovarian tumours. Hum Reprod 2003;18:1681–1685.
   PubMed Web of Science ®Google Scholar
• Ivarsson K, Runesson E, Sundfeldt K, Haeger M, Hedin L, Janson PO, Brannstrom M. The chemotactic cytokine interleukin-8–a cyst fluid marker for malignant epithelial ovarian cancer? Gynecol Oncol 1998;71:420–423.
   PubMed Web of Science ®Google Scholar
• Kanety H, Kattan M, Goldberg I, Kopolovic J, Ravia J, Menczer J, Karasik A. Increased insulin-like growth factor binding protein-2 (IGFBP-2) gene expression and protein production lead to high IGFBP-2 content in malignant ovarian cyst fluid. Br J Cancer 1996;73:1069–1073.
   Google Scholar
• Karasik A, Menczer J, Pariente C, Kanety H. Insulin-like growth factor-I (IGF-I) and IGF-binding protein-2 are increased in cyst fluids of epithelial ovarian cancer. J Clin Endocrinol Metab 1994;78:271–276.
   PubMed Web of Science ®Google Scholar
• Punnonen J, Heinonen PK, Kuoppala T, Jansen CT, Punnonen R. Production of interleukin-1 beta and tumour necrosis factor-alpha in patients with benign or malignant ovarian tumours. J Cancer Res Clin Oncol 1991;117:587–592.
   PubMed Web of Science ®Google Scholar
• Reis FM, Di Blasio AM, Florio P, Ambrosini G, Di Loreto C, Petraglia F. Evidence for local production of inhibin A and activin A in patients with ovarian endometriosis. Fertil Steril 2001;75:367–373.
   PubMed Web of Science ®Google Scholar
• Santala M, Burger H, Ruokonen A, Stenback F, Kauppila A. Elevated serum inhibin and tumor-associated trypsin inhibitor concentrations in a young woman with dysgerminoma of the ovary. Gynecol Oncol 1998;71:465–468.
   PubMed Web of Science ®Google Scholar
• Ott HW, Lindner H, Sarg B, Mueller-Holzner E, Abendstein B, Bergant A, Fessler S, Schwaerzler P, Zeimet A, Marth C, Illmensee K. Calgranulins in cystic fluid and serum from patients with ovarian carcinomas. Cancer Res 2003;63:7507–7514.
   PubMed Web of Science ®Google Scholar
• Beratis NG, Kaperonis A, Eliopoulou MI, Kourounis G, Tzingounis VA. Increased activity of lysosomal enzymes in the peritoneal fluid of patients with gynecologic cancers and pelvic inflammatory disease. J Cancer Res Clin Oncol 2005;131:371–376.
   PubMed Web of Science ®Google Scholar
• Boss EA, Peters WH, Roelofs HM, Boonstra H, Steegers EA, Massuger LF. Glutathione S-transferases P1–1 and A1–1 in ovarian cyst fluids. Eur J Gynaecol Oncol 2001;22:427–432.
   PubMed Web of Science ®Google Scholar
• Haeger M, Swahn M, Hahlin M, Horvath G, Bengtsson A. Increased concentrations of neopterin in plasma, ascites and ovarian cyst fluid in malignant tumours compared with benign ovarian tumours. Anticancer Res 1996;16:3189–3192.
   PubMed Web of Science ®Google Scholar
• Koivunen E, Itkonen O, Halila H, Stenman UH. Cyst fluid of ovarian cancer patients contains high concentrations of trypsinogen-2. Cancer Res 1990;50:2375–2378.
   PubMed Web of Science ®Google Scholar
• Stenman M, Paju A, Hanemaaijer R, Tervahartiala T, Leminen A, Stenman UH, Konttinen YT, Sorsa T. Collagenases (MMP-1, -8 and -13) and trypsinogen-2 in fluid from benign and malignant ovarian cysts. Tumour Biol 2003;24:9–12.
   PubMed Web of Science ®Google Scholar
• Boss EA, Massuger LF, Thomas CM, Geurts-Moespot A, van Schaik JH, Boonstra H, Sweep CG. Clinical value of components of the plasminogen activation system in ovarian cyst fluid. Anticancer Res 2002;22:275–282.
   PubMed Web of Science ®Google Scholar
• Wahlberg K, Hoyer-Hansen G, Casslen B. Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer. Cancer Res 1998;58:3294–3298.
   PubMed Web of Science ®Google Scholar
• Santala M, Risteli J, Risteli L, Puistola U, Kacinski BM, Stanley ER, E. Kauppila A. Synthesis and breakdown of fibrillar collagens: concomitant phenomena in ovarian cancer. Br J Cancer 1998;77:1825–1831.
   PubMed Web of Science ®Google Scholar
• Zhu GG, Melkko J, Risteli J, Kauppila A, Risteli L. Differential processing of type I and type III procollagens in the tumour cysts and peritoneal ascitic fluid of patients with benign and malignant ovarian tumours. Clin Chim Acta 1994;229:87–97.
   PubMed Web of Science ®Google Scholar
• Zhu GG, Risteli J, Puistola U, Kauppila A, Risteli L. Progressive ovarian carcinoma induces synthesis of type I and type III procollagens in the tumor tissue and peritoneal cavity. Cancer Res 1993;53:5028–5032.
   PubMed Web of Science ®Google Scholar
• Furuya M, Ishikura H, Kawarada Y, Ogawa Y, Sakuragi N, Fujimoto S, Yoshiki T. Expression of matrix metalloproteinases and related tissue inhibitors in the cyst fluids of ovarian mucinous neoplasms. Gynecol Oncol 2000;78:106–112.
   PubMed Web of Science ®Google Scholar
• Furuya M, Ishikura H, Ogawa Y, Kawarada Y, Shibata M, Fujimoto S, Yoshiki T. Analyses of matrix metalloproteinases and their inhibitors in cyst fluid of serous ovarian tumors. Pathobiology 2000;68:239–244.
   PubMed Web of Science ®Google Scholar
• Darai E, Bringuier AF, Walker-Combrouze F, Feldmann G, Madelenat P, Scoazec JY. Soluble adhesion molecules in serum and cyst fluid from patients with cystic tumours of the ovary. Hum Reprod 1998;13:2831–2835.
   PubMed Web of Science ®Google Scholar
• Sundfeldt K, Ivarsson K, Rask K, Haeger M, Hedin L, Brannstrom M. Higher levels of soluble E-cadherin in cyst fluid from malignant ovarian tumours than in benign cysts. Anticancer Res 2001;21:65–70.
   PubMed Web of Science ®Google Scholar
• Chudecka-Glaz A, Rzepka-Gorska I, Kosmowska B. Gonadotropin (LH, FSH) levels in serum and cyst fluid in epithelial tumors of the ovary. Arch Gynecol Obstet 2004;270:151–156.
   PubMedGoogle Scholar
• Halperin R, Pansky M, Vaknin Z, Zehavi S, Bukovsky I, Schneider D. Luteinizing hormone in peritoneal and ovarian cyst fluids: a predictor of ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol 2003;110:207–210.
   PubMed Web of Science ®Google Scholar
• Kramer S, Leeker M, Jager W. Gonadotropin levels in ovarian cyst fluids: a predictor of malignancy? Int J Biol Markers 1998;13:165–168.
   PubMed Web of Science ®Google Scholar
• Rzepka-Gorska I, Chudecka-Glaz A, Kosmowska B. FSH and LH serum/tumor fluid ratios and malignant tumors of the ovary. Endocr Relat Cancer 2004;11:315–321.
   PubMed Web of Science ®Google Scholar
• van Nagell JR, Jr., Pletsch QA, Goldenberg DM. A study of cyst fluid and plasma carcinoembryonic antigen in patients with cystic ovarian neoplasms. Cancer Res 1975;35:1433–1437.
   PubMed Web of Science ®Google Scholar
• Arts HJ, de Jong S, Hollema H, Ten Hoor KA, de Vries EG, van der Zee AG. Fas and Fas ligand in cyst fluids, serum and tumors of patients with benign and (borderline) malignant ovarian tumors. Int J Oncol 2005;26:379–384.
   Google Scholar
• Baggerly KA, Morris JS, Coombes KR. Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics (Oxford, England) 2004;20:777–785.
   PubMed Web of Science ®Google Scholar
• Callesen AK, Mogensen O, Jensen AK, Kruse TA, Martinussen T, Jensen ON, Madsen JS. Reproducibility of mass spectrometry based protein profiles for diagnosis of ovarian cancer across clinical studies: a systematic review. J Proteomics 2012;75:2758–2772.
   PubMed Web of Science ®Google Scholar
• Semmes OJ, Feng Z, Adam BL, Banez LL, Bigbee WL, Campos D, Cazares LH, Chan DW, Grizzle WE, Izbicka E, Kagan J, Malik G, McLerran D, Moul JW, Partin A, Prasanna P, Rosenzweig J, Sokoll LJ, Srivastava S, Srivastava S, Thompson I, Welsh MJ, White N, Winget M, Yasui Y, Zhang Z, Zhu L. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem 2005;51:102–112.
   PubMed Web of Science ®Google Scholar
• Jia L, Zhang H, Qu X, Deng B, Kong B. Proteomic analysis reflects different histologic subtypes of epithelial ovarian cancer. Med Hypotheses 2012;78:407–409.
   PubMed Web of Science ®Google Scholar
• Luo J, Qian JH, Yu JK, Zheng S, Xie X, Lu WG. Discovery of altered protein profiles in epithelial ovarian carcinogenesis by SELDI mass spectrometry. Eur J Gynaecol Oncol 2008;29:233–238.
   PubMed Web of Science ®Google Scholar
• Wegdam W, Moerland PD, Meijer D, de Jong SM, Hoefsloot HC, Kenter GG, Buist MR, Aerts JM. A critical assessment of SELDI-TOF-MS for biomarker discovery in serum and tissue of patients with an ovarian mass. Proteome Sci 2012;10:45.
   PubMedGoogle Scholar
• Cadron I, Van Gorp T, Amant F, Vergote I, Moerman P, Waelkens E, Daemen A, Van De Plas R, De Moor B, Zeillinger R. The use of laser microdissection and SELDI-TOF MS in ovarian cancer tissue to identify protein profiles. Anticancer Res 2009;29:1039–1045.
   PubMed Web of Science ®Google Scholar
• Cadron I, Van Gorp T, Moerman P, Waelkens E, Vergote I. Proteomic analysis of laser microdissected ovarian cancer tissue with SELDI-TOF MS. Methods Mol Biol (Clifton, NJ 2011;755:155–163.
   PubMedGoogle Scholar
• Hogdall E, Fung ET, Christensen IJ, Yip C, Nedergaard L, Engelholm SA, Risum S, Petri AL, Lundvall L, Lomas L, Hogdall C. Proteomic biomarkers for overall and progression-free survival in ovarian cancer patients. Proteomics Clin Appl 2010;4:940–952.
   PubMed Web of Science ®Google Scholar
• Hong YJ, Wang XD, Shen D, Zeng S. Discrimination analysis of mass spectrometry proteomics for ovarian cancer detection. Acta Pharmacol Sin 2008;29:1240–1246.
   PubMed Web of Science ®Google Scholar
• Kozak KR, Amneus MW, Pusey SM, Su F, Luong MN, Luong SA, Reddy ST, Farias-Eisner R. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis. Proc Natl Acad Sci U S A 2003;100:12343–12348.
   PubMed Web of Science ®Google Scholar
• Kozak KR, Su F, Whitelegge JP, Faull K, Reddy S, Farias-Eisner R. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 2005;5:4589–4596.
   PubMed Web of Science ®Google Scholar
• Lin YW, Lin CY, Lai HC, Chiou JY, Chang CC, Yu MH, Chu TY. Plasma proteomic pattern as biomarkers for ovarian cancer. Int J Gynecol Cancer 2006;16 (Suppl 1):139–146.
   PubMedGoogle Scholar
• Oh JH, Nandi A, Gurnani P, Knowles L, Schorge J, Rosenblatt KP, Gao JX. Proteomic biomarker identification for diagnosis of early relapse in ovarian cancer. J Bioinform Comput Biol 2006;4:1159–1179.
   PubMedGoogle Scholar
• Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572–577.
   PubMed Web of Science ®Google Scholar
• Petricoin EF, Zoon KC, Kohn EC, Barrett JC, Liotta LA. Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov 2002;1:683–695.
   PubMed Web of Science ®Google Scholar
• Thakur A, Mishra V, Jain SK. Feed forward artificial neural network: tool for early detection of ovarian cancer. Sci Pharm 2011;79:493–505.
   PubMedGoogle Scholar
• Wang J, Zhang X, Ge X, Guo H, Xiong G, Zhu Y. Proteomic studies of early-stage and advanced ovarian cancer patients. Gynecol Oncol 2008;111:111–119.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Bast RC, Jr., Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY, Berchuck A, Van Haaften-Day C, Hacker NF, de Bruijn HW, van der Zee AG, Jacobs IJ, Fung ET, Chan DW. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004;64:5882–5890.
   PubMed Web of Science ®Google Scholar
• Zhang H, Kong B, Qu X, Jia L, Deng B, Yang Q. Biomarker discovery for ovarian cancer using SELDI-TOF-MS. Gynecol Oncol 2006;102:61–66.
   PubMed Web of Science ®Google Scholar
• Moshkovskii SA, Serebryakova MV, Kuteykin-Teplyakov KB, Tikhonova OV, Goufman EI, Zgoda VG, Taranets IN, Makarov OV, Archakov AI. Ovarian cancer marker of 11.7 kDa detected by proteomics is a serum amyloid A1. Proteomics 2005;5:3790–3797.
   PubMed Web of Science ®Google Scholar
• Moshkovskii SA, Vlasova MA, Pyatnitskiy MA, Tikhonova OV, Safarova MR, Makarov OV, Archakov AI. Acute phase serum amyloid A in ovarian cancer as an important component of proteome diagnostic profiling. Proteomics Clin Appl 2007;1:107–117.
   PubMed Web of Science ®Google Scholar
• Su F, Lang J, Kumar A, NG C, Hsieh B, Suchard MA, Reddy ST, Farias-Eisner R. Validation of candidate serum ovarian cancer biomarkers for early detection. Biomark Insights 2007;2:369–375.
   PubMedGoogle Scholar
• Wang Q, Li D, Zhang W, Tang B, Li QQ, Li L. Evaluation of proteomics-identified CCL18 and CXCL1 as circulating tumor markers for differential diagnosis between ovarian carcinomas and benign pelvic masses. Int J Biol Markers 2011;26:262–273.
   PubMed Web of Science ®Google Scholar
• Woong-Shick A, Sung-Pil P, Su-Mi B, Joon-Mo L, Sung-Eun N, Gye-Hyun N, Young-Lae C, Ho-Sun C, Heung-Jae J, Chong-Kook K, Young-Wan K, Byoung-Don H, Hyun-Sun J. Identification of hemoglobin-alpha and -beta subunits as potential serum biomarkers for the diagnosis and prognosis of ovarian cancer. Cancer Sci 2005;96:197–201.
   PubMed Web of Science ®Google Scholar
• Wu SP, Lin YW, Lai HC, Chu TY, Kuo YL, Liu HS. SELDI-TOF MS profiling of plasma proteins in ovarian cancer. Taiwanese J Obstet Gynaecol 2006;45:26–32.
   PubMedGoogle Scholar
• Petri AL, Simonsen AH, Yip TT, Hogdall E, Fung ET, Lundvall L, Hogdall C. Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology. Acta Obstet Gynecol Scand 2009;88:18–26.
   PubMed Web of Science ®Google Scholar
• Bast RC, Jr., Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, Lokshin A, Menon U, Jacobs I, Lu K. New tumor markers: CA125 and beyond. Int J Gynecol Cancer 2005;15 (Suppl 3):274–281.
   PubMed Web of Science ®Google Scholar
• Clarke CH, Yip C, Badgwell D, Fung ET, Coombes KR, Zhang Lu KH, Bast RC Jr. Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer. Gynecol Oncol 2011;122:548–553.
   PubMed Web of Science ®Google Scholar
• Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29–36.
   PubMed Web of Science ®Google Scholar
• Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statistical Society Series B (Methodological) 1995;57:289–300.
   Web of Science ®Google Scholar
• Storey JD, Tibshirani R. Statistical methods for identifying differentially expressed genes in DNA microarrays. Methods Mol Biol (Clifton, NJ) 2003;224:149–157.
   PubMedGoogle Scholar
• Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680–685.
   PubMed Web of Science ®Google Scholar
• Rodbard D. Statistical estimation of the minimal detectable concentration (“sensitivity”) for radioligand assays. Anal Biochem 1978;90:1–12.
   PubMed Web of Science ®Google Scholar
• Spencer CA, Takeuchi M, Kazarosyan M, MacKenzie F, Beckett GJ, Wilkinson E. Interlaboratory/intermethod differences in functional sensitivity of immunometric assays of thyrotropin (TSH) and impact on reliability of measurement of subnormal concentrations of TSH. Clin Chem 1995;41:367–374.
   PubMed Web of Science ®Google Scholar
• van den Bos C, Roth J, Koch HG, Hartmann M, Sorg C. Phosphorylation of MRP14, an S100 protein expressed during monocytic differentiation, modulates Ca(2+)-dependent translocation from cytoplasm to membranes and cytoskeleton. J Immunol 1996;156:1247–1254.
   PubMed Web of Science ®Google Scholar
• O'Farrell PH. High resolution two-dimensional electrophoresis of proteins. J Biol Chem 1975;250:4007–4021.
   PubMed Web of Science ®Google Scholar
• Friedman DB, Hill S, Keller JW, Merchant NB, Levy SE, Coffey RJ, Caprioli RM. Proteome analysis of human colon cancer by two-dimensional difference gel electrophoresis and mass spectrometry. Proteomics 2004;4:793–811.
   PubMed Web of Science ®Google Scholar
• Van den Bergh G, Arckens L. Fluorescent two-dimensional difference gel electrophoresis unveils the potential of gel-based proteomics. Curr Opin Biotechnol 2004;15:38–43.
   PubMed Web of Science ®Google Scholar
• Zhou G, Li H, DeCamp D, Chen S, Shu H, Gong Y, Flaig M, Gillespie JW, Hu N, Taylor PR, Emmert-Buck MR, Liotta LA, Petricoin EF 3rd, Zhao Y. 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Mol Cell Proteomics 2002;1:117–124.
   PubMed Web of Science ®Google Scholar
• von Haller PD, Yi E, Donohoe S, Vaughn K, Keller A, Nesvizhskii AI, En J, Li XJ, Goodlett DR, Aebersold R, Watts JD. The application of new software tools to quantitative protein profiling via isotope-coded affinity tag (ICAT) and tandem mass spectrometry: I. Statistically annotated datasets for peptide sequences and proteins identified via the application of ICAT and tandem mass spectrometry to proteins copurifying with T cell lipid rafts. Mol Cell Proteomics 2003;2:426–427.
   PubMed Web of Science ®Google Scholar
• Gorelik E, Landsittel DP, Marrangoni AM, Modugno F, Velikokhatnaya L, Winans MT, Bigbee WL, Herberman RB, Lokshin AE. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005;14:981–987.
   PubMed Web of Science ®Google Scholar
• Linkov F, Lisovich A, Yurkovetsky Z, Marrangoni A, Velikokhatnaya L, Nolen B, Winans M, Bigbee W, Siegfried J, Lokshin A, Ferris RL. Early detection of head and neck cancer: development of a novel screening tool using multiplexed immunobead-based biomarker profiling. Cancer Epidemiol Biomarkers Prev 2007;16:102–107.
   PubMed Web of Science ®Google Scholar
• Schweitzer B, Roberts S, Grimwade B, Shao W, Wang M, Fu Q, Shu Q, Laroche I, Zhou Z, Tchernev VT, Christiansen J, Velleca M, Kingsmore SF. Multiplexed protein profiling on microarrays by rolling-circle amplification. Nat Biotechnol 2002;20:359–365.
   PubMed Web of Science ®Google Scholar
• Donato R. Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type. Biochim Biophys Acta 1999;1450:191–231.
   PubMed Web of Science ®Google Scholar
• Kerkhoff C, Klempt M, Sorg C. Novel insights into structure and function of MRP8 (S100A8) and MRP14 (S100A9). Biochim Biophys Acta 1998;1448:200–211.
   PubMed Web of Science ®Google Scholar
• Odink K, Cerletti N, Bruggen J, Clerc RG, Tarcsay L, Zwadlo G, Gerhards G, Schlegel R, Sorg C. Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis. Nature 1987;330:80–82.
   PubMed Web of Science ®Google Scholar
• Burwinkel F, Roth J, Goebeler M, Bitter U, Wrocklage V, Vollmer E, Roessner A, Sorg C, Bocker W. Ultrastructural localization of the S-100-like proteins MRP8 and MRP14 in monocytes is calcium-dependent. Histochemistry 1994;101:113–120.
   PubMedGoogle Scholar
• Roth J, Burwinkel F, van den Bos C, Goebeler M, Vollmer E, Sorg C. MRP8 and MRP14, S-100-like proteins associated with myeloid differentiation, are translocated to plasma membrane and intermediate filaments in a calcium-dependent manner. Blood 1993;82:1875–1883.
   PubMed Web of Science ®Google Scholar
• Teigelkamp S, Bhardwaj RS, Roth J, Meinardus-Hager G, Karas M, Sorg C. Calcium-dependent complex assembly of the myeloic differentiation proteins MRP-8 and MRP-14. J Biol Chem 1991;266:13462–13467.
   PubMed Web of Science ®Google Scholar
• Rammes A, Roth J, Goebeler M, Klempt M, Hartmann M, Sorg C. Myeloid-related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway. J Biol Chem 1997;272:9496–9502.
   PubMed Web of Science ®Google Scholar
• Hogg N, Allen C, Edgeworth J. Monoclonal antibody 5.5 reacts with p8,14, a myeloid molecule associated with some vascular endothelium. Eur J Immunol 1989;19:1053–1061.
   PubMed Web of Science ®Google Scholar
• Newton RA, Hogg N. The human S100 protein MRP-14 is a novel activator of the beta 2 integrin Mac-1 on neutrophils. J Immunol 1998;160:1427–1435.
   PubMed Web of Science ®Google Scholar
• Murao S, Collart FR, Huberman E. A protein containing the cystic fibrosis antigen is an inhibitor of protein kinases. J Biol Chem 1989;264:8356–8360.
   PubMed Web of Science ®Google Scholar
• Odegaard E, Davidson B, Elgaaen BV, Fagerhol MK, Engh V, Onsrud M, Staff AC. Circulating calprotectin in ovarian carcinomas and borderline tumors of the ovary. Am J Obstet Gynecol 2008;198:418 e1–7.
   PubMedGoogle Scholar
• Goebeler M, Roth J, van den Bos C, Ader G, Sorg C. Increase of calcium levels in epithelial cells induces translocation of calcium-binding proteins migration inhibitory factor-related protein 8 (MRP8) and MRP14 to keratin intermediate filaments. Biochem J 1995;309 (Pt 2):419–424.
   PubMedGoogle Scholar
• Madsen P, Rasmussen HH, Leffers H, Honore B, Celis JE. Molecular cloning and expression of a novel keratinocyte protein (psoriasis-associated fatty acid-binding protein [PA-FABP]) that is highly up-regulated in psoriatic skin and that shares similarity to fatty acid-binding proteins. J Invest Dermatol 1992;99:299–305.
   PubMed Web of Science ®Google Scholar
• Wilkinson MM, Busuttil A, Hayward C, Brock DJ, Dorin JR, Van Heyningen V. Expression pattern of two related cystic fibrosis-associated calcium-binding proteins in normal and abnormal tissues. J Cell Sci 1988;91 (Pt 2):221–230.
   PubMed Web of Science ®Google Scholar
• Boussac M, Garin J. Calcium-dependent secretion in human neutrophils: a proteomic approach. Electrophoresis 2000;21:665–672.
   PubMed Web of Science ®Google Scholar
• Zwadlo G, Bruggen J, Gerhards G, Schlegel R, Sorg C. Two calcium-binding proteins associated with specific stages of myeloid cell differentiation are expressed by subsets of macrophages in inflammatory tissues. Clin Exp Immunol 1988;72:510–515.
   PubMed Web of Science ®Google Scholar
• Kavsak PA, Lee A, Hirte H, Young E, Gauldie J. Cytokine elevations in acute coronary syndrome and ovarian cancer: a mechanism for the up-regulation of the acute phase proteins in these different disease etiologies. Clin Biochem 2008;41:607–610.
   PubMed Web of Science ®Google Scholar
• Anderson GL, McIntosh M, Wu L, Barnett M, Goodman G, Thorpe JD, Bergan L, Thornquist MD, Scholler N, Kim N, O'Briant K, Drescher C, Urban N. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst 2010;102:26–38.
   PubMed Web of Science ®Google Scholar
• Jungblut PR, Zimny-Arndt U, Zeindl-Eberhart E, Stulik J, Koupilova K, Pleissner KP, Otto A, Muller EC, Sokolowska-Kohler W, Grabher G, Stoffler G. Proteomics in human disease: cancer, heart and infectious diseases. Electrophoresis 1999;20:2100–2110.
   PubMed Web of Science ®Google Scholar
• Stulik J, Kovarova H, Macela A, Bures J, Jandik P, Langr F, Otto A, Thiede B, Jungblut P. Overexpression of calcium-binding protein calgranulin B in colonic mucosal diseases. Clin Chim Acta 1997;265:41–55.
   PubMed Web of Science ®Google Scholar
• Stulik J, Osterreicher J, Koupilova K, Knizek, Macela A, Bures J, Jandik P, Langr F, Dedic K, Jungblut PR. The analysis of S100A9 and S100A8 expression in matched sets of macroscopically normal colon mucosa and colorectal carcinoma: the S100A9 and S100A8 positive cells underlie and invade tumor mass. Electrophoresis 1999;20:1047–1054.
   PubMed Web of Science ®Google Scholar
• Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai CO, Bast RC Jr. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008;108:402–408.
   PubMed Web of Science ®Google Scholar
• Luo LY, Katsaros D, Scorilas A, Fracchioli S, Bellino R, van Gramberen M, de Bruijn H, Henrik A, Stenman UH, Massobrio M, van der Zee AG, Vergote I, Diamandis EP. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res 2003;63:807–811.
   PubMed Web of Science ®Google Scholar
• Baron AT, Boardman CH, Lafky JM, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005;14: 306–318.
   PubMed Web of Science ®Google Scholar
• Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, Winget M, Yasui Y. Phases of biomarker development for early detection of cancer. JNCI Cancer Spectr 2001;93:1054–1061.
   PubMed Web of Science ®Google Scholar